Clinical Trial: Rivastigmine Nano-micron Tablets for Alzheimer's Disease

U.S., Feb. 15 -- ClinicalTrials.gov registry received information related to the study (NCT06828289) titled 'Rivastigmine Nano-micron Tablets for Alzheimer's Disease' on Feb. 11.

Brief Summary: The purpose of this study is to investigate the efficacy and safety of rivastigmine micron-tablets in patients with mild with mild or moderate Alzheimer's disease (AD).

Study Start Date: Feb. 28

Study Type: OBSERVATIONAL

Condition: Alzheimer's Disease

Intervention: DRUG: Rivastigmine Nano-micron Tablets

Treatment group: Rivastigmine Nano-micron Tablets

DRUG: Donepezil Hydrochloride

Control group: Donepezil

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Peking University First Hospital

Published by HT Digital Content Services with pe...